Table 1. Sub-cohorts of the SUPER-GUC and their eligibility criteria.

Cohort	Eligibility criteria
SUPER-PC
SUPER-PC-RP	Pathologically proven prostate cancer patients who undergo radical prostatectomy
SUPER-PC-AS	Pathologically proven low risk prostate cancer patients within 6 months who undergo active surveillance as initial treatment. They should be eligible by strict criteria registered in ClinicalTrials.gov protocol (NCT02971085), when patients want and meet usual active surveillance criteria they can be enrolled as non-strict criteria.
SUPER-PC-RT	Pathologically proven prostate cancer patients who undergo radiation therapy with curative intent. It includes primary, adjuvant and salvage radiation therapy, but palliative radiation therapy is not eligible.
SUPER-PC-HSPC	Pathologically proven non-metastatic or metastatic hormone sensitive prostate cancer patients who undergo medical therapy as major initial treatment. It includes watchful waiting, ADT and chemo-ADT. Neoadjuvant or adjuvant medical therapy for other major treatment is not eligible.
SUPER-PC-CRPC	Pathologically proven prostate cancer patients, who were progressed as CRPC within 3 months.
SUPER-RCC
SUPER-RCC-Nx	Clinically diagnosed as renal cell carcinoma patients who undergo surgical treatment. It includes ablation, partial or radical nephrectomy. It is not limited to localized cancer, thus cytoreductive nephrectomy in metastatic disease is also eligible.
SUPER-RCC-mRCC	Pathologically proven renal cell carcinoma patients who were diagnosed as advanced (T4 or N1) or metastatic disease within 3 months and undergo initial treatment for advanced or metastatic RCC. Nephrectomy or metastasectomy before pathologic diagnosis does not limit the enrollment.
SUPER-UC
SUPER-UC-TURB	Clinically diagnosed as bladder cancer patients who undergo transurethral resection of bladder tumor.
SUPER-UC-Cx	Pathologically proven bladder cancer patients who undergo radical cystectomy.
SUPER-UC-UTUC	Clinically diagnosed as upper urinary tract urothelial cancer patients who undergo curative surgical treatment for it. It includes nephroureterectomy, segmental ureterectomy and any kind of nephron sparing endoscopic treatment. It also includes definitive treatment plan after intraoperative decision by ureteroscopy with or without frozen biopsy.
SUPER-UC-mUC	Pathologically proven urothelial cancer patients who were diagnosed as advanced (non-localized or lymph node involve- ment) or metastatic disease within 3 months and undergo initial treatment for advanced or metastatic urothelial cancer.

SUPER, Seoul National University Prospectively Enrolled Registry; GUC, Genitourinary Cancer; PC, prostate cancer; RP, radical prostatectomy; AS, active surveillance; RT, radiation therapy; HSPC, hormone-sensitive prostate cancer; ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; RCC, renal cell carcinoma; Nx, nephrectomy; mRCC, metastatic renal cell carcinoma; UC, urothelial cancer; TURB, transurethral resection of bladder tumor; Cx, cystectomy; UTUC, upper urinary tract urothelial cancer; mUC, metastatic urothelial cancer.